The chemistry of catechol-O-methyltransferase inhibitors
- PMID: 21095461
- DOI: 10.1016/B978-0-12-381326-8.00006-5
The chemistry of catechol-O-methyltransferase inhibitors
Abstract
Despite several drawbacks, levodopa (L-dopa) remains the gold standard drug for treatment of the symptoms of Parkinson's disease (PD). L-dopa is a pro-drug of dopamine and is used to elevate striatal levels of the neurotransmitter. One approach to provide a more continuous and sustained delivery of dopamine has targeted one of the principal enzymes responsible for metabolic deactivation of L-dopa, namely catechol-O-methyltransferase (COMT). The chapter will provide a perspective of the medicinal chemistry behind the discovery of several COMT inhibitors and discuss how certain physicochemical parameters, including aqueous solubility and lipophilicity, are thought to influence pharmacokinetic properties such as absorption, distribution, and bioavailability.
Copyright © 2010 Elsevier Inc. All rights reserved.
Similar articles
-
Biochemistry and pharmacology of catechol-O-methyltransferase inhibitors.Int Rev Neurobiol. 2010;95:73-118. doi: 10.1016/B978-0-12-381326-8.00005-3. Int Rev Neurobiol. 2010. PMID: 21095460 Review.
-
Catechol-O-methyltransferase in complex with substituted 3'-deoxyribose bisubstrate inhibitors.Acta Crystallogr D Biol Crystallogr. 2012 Mar;68(Pt 3):253-60. doi: 10.1107/S0907444912001138. Epub 2012 Feb 14. Acta Crystallogr D Biol Crystallogr. 2012. PMID: 22349227
-
Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.Int Rev Neurobiol. 2010;95:1-5. doi: 10.1016/B978-0-12-381326-8.00001-6. Int Rev Neurobiol. 2010. PMID: 21095456 Review.
-
Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility.J Med Chem. 2014 Nov 13;57(21):8692-717. doi: 10.1021/jm500572b. Epub 2014 Sep 2. J Med Chem. 2014. PMID: 25080080
-
Favorable effect of catechol-O-methyltransferase inhibition by OR-462 in experimental models of Parkinson's disease.J Pharmacol Exp Ther. 1988 Oct;247(1):289-93. J Pharmacol Exp Ther. 1988. PMID: 3171977
Cited by
-
Synthesis and Evaluation of Heterocyclic Catechol Mimics as Inhibitors of Catechol-O-methyltransferase (COMT).ACS Med Chem Lett. 2015 Jan 26;6(3):318-23. doi: 10.1021/ml500502d. eCollection 2015 Mar 12. ACS Med Chem Lett. 2015. PMID: 25815153 Free PMC article.
-
The structural biology of oestrogen metabolism.J Steroid Biochem Mol Biol. 2013 Sep;137:27-49. doi: 10.1016/j.jsbmb.2012.12.014. Epub 2013 Jan 4. J Steroid Biochem Mol Biol. 2013. PMID: 23291110 Free PMC article. Review.
-
Optimization of 8-Hydroxyquinolines as Inhibitors of Catechol O-Methyltransferase.J Med Chem. 2018 Nov 8;61(21):9647-9665. doi: 10.1021/acs.jmedchem.8b01126. Epub 2018 Oct 19. J Med Chem. 2018. PMID: 30272964 Free PMC article.
-
Synthesis and Evaluation of Bicyclic Hydroxypyridones as Inhibitors of Catechol O-Methyltransferase.ACS Med Chem Lett. 2019 Oct 22;10(11):1573-1578. doi: 10.1021/acsmedchemlett.9b00345. eCollection 2019 Nov 14. ACS Med Chem Lett. 2019. PMID: 32038769 Free PMC article.
-
Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor.Clin Pharmacokinet. 2013 Feb;52(2):139-51. doi: 10.1007/s40262-012-0024-7. Clin Pharmacokinet. 2013. PMID: 23248072 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous